Phase 3 N=8 Randomized Quadruple-blind Treatment

Glycine vs Placebo for the Schizophrenia Prodrome

Schizophrenia Prodrome

Bottom Line

View on ClinicalTrials.gov: NCT00291226 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2016

Primary outcome: Primary: Scale of Prodromal Symptoms Total Score — 37.8; 37.5 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Glycine (Drug); Placebo (Drug)
Age: Pediatric, Adult · 13+ yrs
Sex: All
Sponsor: Yale University
Primary completion: Jul 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Scale of Prodromal Symptoms Total Score	37.8; 37.5	—
PRIMARY Change in Scale of Prodromal Symptoms Total Score	-5.8; 4.5	—

Summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Eligibility Criteria

Inclusion Criteria

meet SIPS criteria for schizophrenia prodrome

Exclusion Criteria

history of psychosis

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00291226). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.